Multiple Sclerosis Trial, Recruiting NCT07353216 Sponsor: Third Affiliated Hospital, Sun Yat-Sen University Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT07353216
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing to sign and date a consent form before taking part in the study.
  • You must be 18 years old or older at the time of joining the study.
  • You must have been diagnosed with relapsing multiple sclerosis (RMS) based on specific medical guidelines from 2017.
  • Your level of disability, measured on a standard scale, must fall within a certain range (from no disability up to needing some help walking — confirm with trial site).
  • You must have regular check-ups that include MRI brain or spine scans.
  • You must be willing to provide blood samples during the study.
  • You must be willing to take part in health assessments, including physical examinations and questionnaires.

Who may not be able to join:

  • You or your legal guardian have decided you do not wish to continue or participate.
  • You are currently pregnant.
  • You have been diagnosed with a serious brain infection called Progressive Multifocal Leukoencephalopathy (PML).
  • You have had a severe allergic reaction to the medicine being studied.
  • There has been a breach of the study rules that puts your safety at risk.
  • You have developed certain serious health conditions, such as cancer, severe liver failure, or serious ongoing infections like active hepatitis B or HIV.
  • You have abnormal blood or lab test results that the medical team believes make it unsafe for you to continue in the study.
  • You have any other health condition that the medical team believes makes it unsafe for you to take part.
  • You have not been following the study instructions or taking the study medicine as required.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Ofatumumab treatment reduces sNfL levels in patients with Relapsing Multiple Sclerosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov